Signed in as:
filler@godaddy.com
We turn badly behaved molecules into smart formulations.
We are an award winning formulation development CDMO. We turn badly behaved molecules into smart formulations which gives them the best chance of success in preclinical studies, and enables them to be accelerated to clinic and commercial.
Our core expertise is in developing formulations for small molecules and peptides for a range of routes of administration including: oral, ocular, intranasal and topical.
When developing formulations we consider:
How badly behaved is the molecule? What are the characteristics which need to be formulated out or around? For example, poor solubility, permeability, stability and/or release profile.
How far does the client want to take the product? For example GLP tox, Phase I, Phase II, commercial? How futureproof does the formulation need to be?
What are the imminent study requirements? For example dose, route of administration and, of course, the timelines?
What species will the formulations be assessed in? This will help us to determine which formats can be used and select excipients at appropriate levels.
Our Futureproof Formulations Fast™ approach creates formulations which give the molecule the best chance of success in the imminent studies, and enable it to be accelerated on to clinic.
All activities are fee for service, all IP generated belongs to the Client.
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators.
MANCHESTER, United Kingdom and HYDERABAD, India, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing.
Through this partnership, customers will have access to integrated drug substance and drug product development, helping them move efficiently from preclinical studies to first-in-human (FIH) clinical trials and beyond.
Unified expertise, seamless execution
By combining deep expertise across the CMC value chain, the Integrated CMC Partnership helps customers create and execute holistic development plans—translating molecular hits into new medicines. Key benefits include:
The result is a faster, more efficient, and more collaborative pathway for innovators to advance their drug candidates with confidence.
Quotes from the partners
"We are delighted to partner with Agility Life Sciences and Centrix Pharma in this truly integrated CMC offering. By bringing together our complementary strengths, we can deliver far greater value to innovators—helping them translate ideas into medicines with speed, quality, and efficiency. This partnership reflects our shared commitment to supporting customers on their journey from discovery to the clinic, and ultimately, to patients.” — Krishna Kanumuri, MD & CEO, Sai Life Sciences
“We are delighted to be entering this partnership with Sai and Centrix. Our combined expertise and energy will enable our clients’ molecules to be accelerated through key milestones, while reducing risk and cost.” — Dr Claire Thompson, CEO and Founder, Agility Life Sciences.
“What excites me most about this partnership is the spirit of collaboration it represents. By bringing together talented teams across Sai, Agility, and Centrix, we are creating a seamless environment where expertise flows freely, challenges are solved collectively, and clients benefit from true alignment. At its heart, this is about people working side by side to turn promising science into medicines that can change lives.” — Chris Davison, CEO, Centrix Pharma Solutions.
About Sai Life Sciences
Sai Life Sciences is a leading integrated Contract Research, Development & Manufacturing Organization (CRDMO) working with over 300 innovator pharma and biotech companies globally to accelerate the discovery, development, and manufacture of complex small molecules. With over 3,400 employees, state-of-the-art facilities in India, UK, and USA, and a strong focus on sustainability, Sai enables customers to bring new medicines to patients faster. www.sailife.com | contact@sailife.com
About Agility Life Sciences
Agility Life Sciences is an award-winning formulation development CDMO helping pharmaceutical and biotech companies overcome bioavailability, stability, and delivery challenges. Known for its problem-solving expertise and flexible approach, Agility’s “Fast Futureproof Formulations” approach creates tailored formulations that enable molecules to progress rapidly into and through the clinic. www.agilitylifesciences.com | info@agilitylifesciences.com
About Centrix Pharma Solutions
Centrix Pharma Solutions is a specialist CDMO focused on drug product development and clinical trial manufacturing. Building on decades of expertise, we provide science-driven, patient-centric solutions that accelerate the journey from molecule to medicine, combining technical depth, flexible execution, and a commitment to quality that delivers value for partners and patients alike. www.centrixpharmasolutions.com | info@centrixpharmasolutions.com
We know that our Clients have unique needs. Send us a message, and we will get back to you soon.
Springcourt House, High Street, Stapleford, Nottingham, UK
Agility Life Sciences
Agility Life Sciences, Springcourt House, High Street, Stapleford, Nottingham, NG9 8AG